Prediction of HIV-1 protease inhibitor resistance by Molecular Modeling Protocols (MMPs) using GenMol™ software

European Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2008, Pages 2518-2534

  Pepe G ^a   Courcambeck, J ^b   Perbost, R ^b   Jouanna, P ^a,c   Halfon, P ^b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Genoscience   (France)

^c UNIVERSITÉ MONTPELLIER 2   (France)

Author keywords

GenMol ; HIV mutations; HIV resistance; Molecular modeling

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CHEMICAL STRUCTURE; COMPUTER PROGRAM; DRUG BINDING; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; PHENOTYPE; SIMULATION; STEREOSPECIFICITY;

EID: 54149101792     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.02.046     Document Type: Article

References (23)

1. Pèpe G., and Siri D. GENMOL: A Fast Software for Molecular Modeling. Application to the Determination of the Psychotonic or Sedative Effects of Tricyclic Antidepressant Drugs. In: Rivail J.L. (Ed). Modelling of Molecular Structure and Properties (1990), Elsevier, Amsterdam 93-101
2. von der Helm K. Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. Biol. Chem. 377 12 (1996) 765-774
3. Weber I.T., and Harrison R.W. Molecular mechanics analysis of drug-resistant mutants of HIV protease. Protein Eng. 12 (1999) 469-474
4. Lee K., and Chu C.K. Molecular modeling approach to understanding the mode of action of l-nucleosides as antiviral agents. Antiviral Chem. Chemother. 9 (2001) 187-203
5. Altmann A., Beerenwinkel N., Sing T., Savenkov I., Däumer M., Kaiser R., Rhee S.-Y., Fessel W.J., Shafer R.W., and Lengauer T. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antiviral Ther. 12 (2007) 169-178
6. Volarath P., Harrison R.W., and Weber I.T. Structure based drug design for HIV protease: from molecular modeling to cheminformatics. Curr Top Med Chem 7 10 (2007) 1030-1038
7. Erhardt P.W. Medicinal chemistry in the new millennium. A glance into the future (special topic article). Pure Appl. Chem. 74 5 (2002) 703-785
8. Shenderovich M.D., Kagan R.M., Heseltine P.N.R., and Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci. 12 (2003) 1706-1718
9. Jenwitheesuk E., and Samudrala R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antiviral Ther. 10 (2005) 157-166
10. Del Re G. A simple MO-LCAO method for the calculation of charges distributions in saturated organic molecules. J. Chem. Soc. (1958) 4031-4040
11. Pèpe G., Serres B., Laporte D., Del Re G., and Minichino C. Surface electrostatic potentials on macromolecules in a monopole approximation: a computer program and an application to cytochromes. J. Theor. Biol. 115 4 (1985) 571-593
12. Cavelier-Frontin F., Pèpe G., Verducci J., Siri D., and Jacquier R. Prediction of the best linear precursor in the synthesis of cyclotetrapeptides by molecular mechanics calculations. J. Am. Chem. Soc. 114 (1992) 8885-8890
13. Pèpe G., Meyer M., Faury P., Graciet J.C., Chermann J.C., and Kraus J.L. A model allowing the design of modified nucleosides as HIV-RT inhibitors. Eur. J. Med. Chem. 31 (1996) 775-786
14. Lin C.H., Gabas N., Canselier J.P., and Pèpe G. Prediction of the growth morphology of aminoacid crystals in solution. I. α-Glycine. J. Cryst. Growth 191 (1998) 791-802
15. Courcambeck J., Bouzidi M., Perbost R., Jouirou B., Amrani N., Cacoub P., Pèpe G., Sabatier J.M., and Halfon P. Resistance of Hepatitis C Virus to NS3-4A protease inhibitors: mechanims of drug resistance induced by R155Q, A156T, D168A and 168V mutations. Antiviral Ther. 11 (2006) 847-855
16. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
17. Stouten P.F.W., Frömmel C., and Nakamura H. An effective solvation term based on atomic occupancies for use in protein simulations. Mol. Simul. 10 (1993) 97-120
18. Schapira M., Totrov M., and Abagyan R. Prediction of the binding energy for small molecules, peptides and proteins. J. Mol. Recognit. 12 (1999) 177-186
19. Shenderovich M.D., Tseitin V., Fisher C.L., and Ramnarayan K. Molecular Modeling and Binding Energy Calculations for Drug Resistant Mutations in HIV-1 Protease-inhibitor Complexes. In: Lebl M., and Houghten R.A. (Eds). Peptides: The Wave of the Future. Proceedings of the Second International and the 17th American Peptide Symposium (2001), American Peptide Society, San Diego, CA 418-419
20. Maschera B., Darby G., Palú G., Wright L.L., Tisdale M., Myers R., Blair E.D., and Furfine E.S. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271 52 (1996) 33231-33235
21. Martin P., Vickrey J.F., Proteasa G., Jimenez Y.L., Wawrzak Z., Winters A., Merigan T.C., and Kovari L.C. "Wide-open" 1.3 Å structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 13 12 (2005) 1887-1895
22. Mahalingam B., Wang Y.F., Boross P.I., Tozser J., Louis J.M., Harrison R.W., and Weber I.T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur. J. Biochem. 271 8 (2004) 1516-1524
23. Hong L., Zhang X.C., Hartsuck J.A., and Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9 10 (2000) 1898-1904